Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21056089 | 1.00 | SMN1; SMN2 (0.62) | SMN1; SMN2HPGDCYP1A2GLACYP3A4 | |
| SCHEMBL12656154 | 0.87 | TSHR (0.50) | SMN1; SMN2HPGDCYP1A2GLACYP3A4 | |
| SCHEMBL12718928 | 0.85 | TSHR (0.74) | SMN1; SMN2ALOX12GAALMNATSHR | |
| SCHEMBL8505592 | 0.85 | TSHR (0.74) | SMN1; SMN2ALOX12GAALMNATSHR | |
| Rac-Dichlorprop SCHEMBL28260779 | 0.85 | TSHR (0.69) | SMN1; SMN2HPGDCYP1A2GLACYP3A4 | |
| SCHEMBL10964062 | 0.85 | FFAR1 (0.57) | SMN1; SMN2HPGDCYP1A2GLACYP3A4 | |
| (S)-Dichlorprop SCHEMBL1535831 | 0.85 | TSHR (0.73) | SMN1; SMN2HPGDCYP1A2GLACYP3A4 | |
| SCHEMBL7750963 | 0.85 | SMN1; SMN2 (0.64) | SMN1; SMN2HPGDCYP1A2GLACYP3A4 | |
| SCHEMBL9780720 | 0.85 | SMN1; SMN2 (0.64) | SMN1; SMN2HPGDCYP1A2GLACYP3A4 | |
| (R)-Dichlorprop SCHEMBL55175 | 0.85 | TSHR (0.73) | SMN1; SMN2HPGDCYP1A2GLACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4017244-B1 | APPARATUS AND METHOD FOR REDUCING DUST DEVELOPMENT IN PRECISION DRILL SOWING | SYNGENTA CROP PROTECTION AG (CH) | 2025-03-12 | — | — | EP | disclosed |
| CN-114958775-B | Rice blast amide artificial antigen, monoclonal antibody, hybridoma cell strain and application thereof | 江南大学 | 2023-04-07 | — | — | CN | disclosed |
| CN-108463460-B | Microbiocidal oxadiazole derivatives | 先正达参股股份有限公司 | 2022-10-28 | — | — | CN | disclosed |
| EP-3683213-B1 | INTERMEDIATE FOR THE PREPARATION OF MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2022-10-12 | — | — | EP | disclosed |
| CN-114958775-A | Rice blast amide artificial antigen, monoclonal antibody, hybridoma cell strain and application thereof | 江南大学 | 2022-08-30 | — | — | CN | disclosed |
| EP-4017244-A1 | APPARATUS AND METHOD FOR REDUCING DUST DEVELOPMENT IN PRECISION DRILL SOWING | SYNGENTA PARTICIPATIONS AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-4017241-A1 | PRECISION TREATMENT AND SOWING OR PLANTING METHOD AND DEVICE | SYNGENTA PARTICIPATIONS AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-4017242-A1 | APPARATUS AND METHOD FOR CONVERTING EXISTING SOWING EQUIPMENT | SYNGENTA PARTICIPATIONS AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-4017243-A1 | HIGH PRECISION GREENHOUSE SEED AND SEEDLING TREATMENT | SYNGENTA PARTICIPATIONS AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-4017245-A1 | SOWING DEVICE AND METHOD FOR TREATING SEEDS DURING PLANTING | SYNGENTA PARTICIPATIONS AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-3498273-A1 | PHARMACEUTICAL COMPOSITION FOR MODULATING THE RESPONSE OF A GABA-A RECEPTOR | Universität Wien (AT) | 2019-06-19 | — | — | EP | disclosed |
| US-8242103-B2 | Sulphamides for treatment of cancer | MERCK SHARP & DOHME LIMITED (GB) | 2012-08-14 | — | — | US | disclosed |
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| EP-1885349-A2 | SULPHAMIDES FOR TREATMENT OF CANCER | Merck Sharp & Dohme Limited (GB) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006123185-A2 | SULPHAMIDES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
| US-7138400-B2 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-21 | — | — | US | disclosed |
| EP-1334085-B1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME (GB) | 2005-08-24 | — | — | EP | disclosed |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2004-03-11 | — | — | US | disclosed |
| EP-1334085-A1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LTD. (GB) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002036555-A1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | SDHA, SDHB, BRDT | SMN1; SMN2 1402/4885HPGD 587/4885CYP1A2 1359/4885 |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | SMN1; SMN2 584/4885HPGD 2161/4885CYP1A2 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.